Cempra (CEMP) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Cempra Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
February 25, 2015 4:00 PM ESTCHAPEL HILL, N.C., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter and year ended December 31, 2014 and provided an update on recent corporate developments. The company will host a webcast and conference call today at 4:30 p.m. EST.
Fourth Quarter 2014 and Recent Corporate Highlights
In November 2014, Cempra received authorization for the next phase of its existing contract with the Biomedical Advanced Research and... More